Krystal Biotech
KRYS
113 hedge funds and large institutions have $1.11B invested in Krystal Biotech in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 54 increasing their positions, 30 reducing their positions, and 13 closing their positions.
80% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 30
0% more funds holding
Funds holding: 113 → 113 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
0.37% less ownership
Funds ownership: 74.22% → 73.85% (-0.37%)
12% less capital invested
Capital invested by funds: $1.27B → $1.11B (-$153M)
56% less call options, than puts
Call options by funds: $3.95M | Put options by funds: $9.03M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.7M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$12M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$9.81M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$7.86M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.77M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$38.4M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$10.7M |
| 4 |
FM
Frazier Management
Seattle,
Washington
|
-$7.48M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$6.93M |
KRYS Hedge Fund Activity: Q2 2021 in Review
113 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q2 2021, worth a combined $1.11B — down 12% from $1.27B a quarter earlier.
Fund positioning in KRYS was balanced in Q2 2021: 13 funds opened new positions, 13 closed out, 54 added to existing stakes and 30 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $29.7M. The largest seller was Farallon Capital Management, cutting an estimated $38.4M.
- 113 institutional investors held Krystal Biotech (KRYS) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $1.11B of Krystal Biotech stock for Q2 2021, down 12% quarter-over-quarter.
- 13 funds opened new Krystal Biotech positions in Q2 2021 and 13 closed out, a net change of 0 holders.
- The largest Krystal Biotech buyer in Q2 2021 was Fidelity Investments, an estimated $29.7M added.
- The largest Krystal Biotech seller in Q2 2021 was Farallon Capital Management, an estimated $38.4M sold.
Based on aggregated 13F filings for Q2 2021.